Literature DB >> 30266239

Subchronic (90-day) repeated dose toxicity study of 2-hydroxybenzylamine acetate in rats.

John C Fuller1, Lisa M Pitchford2, Naji N Abumrad3, John A Rathmacher4.   

Abstract

2-Hydroxybenzylamine (2-HOBA), a naturally occurring compound found in buckwheat, can protect cells and tissues from oxidative stress. In this study, 2-HOBA acetate was orally administered to male and female rats for 90 consecutive days at doses of 100, 500, and 1000 mg·kg BW-1·d-1 (n = 20 per sex/group). Subchronic administration of 2-HOBA was well tolerated at all dose levels. 2-HOBA-treated male rats were slightly heavier in the last weeks of the study, but this difference was very small (<5%), did not show a dose-response relationship, and was not observed in female rats. Similarly, some statistically significant changes in serum biochemistry and hematology parameters were noted, but these were not considered to be of biological or toxicological significance. Sporadic differences in organ weights were observed between groups, but all were small (<10%) and unlikely to indicate toxicity. The incidence of histopathological lesions was similar between treated and control groups across all organs. Based upon these findings, the no-observed-adverse-effect level was determined to be ≥ 1000 mg·kg BW-1·d-1, which was the highest dose tested. These results further support no toxicity associated with oral consumption of 2-HOBA acetate in rats and the continued development of 2-HOBA as a dietary supplement or functional food.
Copyright © 2018 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Preclinical; Rodent; Safety; Salicylamine; γ-Ketoaldehydes

Mesh:

Substances:

Year:  2018        PMID: 30266239     DOI: 10.1016/j.yrtph.2018.09.025

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  3 in total

Review 1.  Isolevuglandins as mediators of disease and the development of dicarbonyl scavengers as pharmaceutical interventions.

Authors:  Sean S Davies; Linda S May-Zhang; Olivier Boutaud; Venkataraman Amarnath; Annet Kirabo; David G Harrison
Journal:  Pharmacol Ther       Date:  2019-10-16       Impact factor: 12.310

2.  First-in-human study assessing safety, tolerability, and pharmacokinetics of 2-hydroxybenzylamine acetate, a selective dicarbonyl electrophile scavenger, in healthy volunteers.

Authors:  Lisa M Pitchford; John A Rathmacher; John C Fuller; J Scott Daniels; Ryan D Morrison; Wendall S Akers; Naji N Abumrad; Venkataraman Amarnath; Patricia M Currey; L Jackson Roberts; John A Oates; Olivier Boutaud
Journal:  BMC Pharmacol Toxicol       Date:  2019-01-05       Impact factor: 2.483

3.  Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial.

Authors:  Lisa M Pitchford; Patricia M Driver; John C Fuller; Wendell S Akers; Naji N Abumrad; Venkataraman Amarnath; Ginger L Milne; Sheau-Chiann Chen; Fei Ye; L Jackson Roberts; M Benjamin Shoemaker; John A Oates; John A Rathmacher; Olivier Boutaud
Journal:  BMC Pharmacol Toxicol       Date:  2020-01-06       Impact factor: 2.483

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.